The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy

Treatments in Endocrinology

Volumn 5, Issue 4, 2006, Pages 211-222

  Abaterusso, Cataldo ^a   Gambaro, Giovanni ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; CHONDROITIN; DANAPAROID; DERMATAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARIN; PHOSPHOTRANSFERASE INHIBITOR; STATIN; SULODEXIDE; TINZAPARIN;

ALBUMINURIA; BASEMENT MEMBRANE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST OF ILLNESS; DEMENTIA; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; META ANALYSIS; METABOLIC REGULATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; CHRONIC KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 33746691250     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605040-00002     Document Type: Review

References (86)

1. Arkouche W, Traeger J, Delawari E, et al. Twenty-five years of experience with out-center hemodialysis. Kidney Int 1999; 56: 2269-75
2. Johnson JG, Gore SM, Firth J. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant 1999; 14: 2156-64
3. Gilbert RE, Cooper ME, McNally PG, et al. Microalbuminuria: prognostic and therapeutic implications of diabetes mellitus. Diabet Med 1994; 11: 636-45
4. Borch-Johnsen K, Kreiner S. Proteinuria value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294: 1651-4
5. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996; 313: 779-84
6. Deckert T. Glycemic control and complications. In: Alberti KGMM, Krall LP, editors. The diabetes annual 4. Amsterdam: Elsevier Science Publishers BV, 1988: 496-518
7. Osterby R. Glomerular structural changes in type I diabetes mellitus: causes, consequences, and prevention. Diabetologia 1992; 35: 803-12
8. Kofoed-Enedvoldsen A. Heparan sulphate in the pathogenesis of diabetic nephropathy. Diabetes Metab Rev 1995; 11: 137-60
9. Gambaro G, Ceol M, Antonello A. The Steno hypothesis for cardiovascular and renal disease revisited. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. 6th ed. Boston (MA): Kluwer Academic Publishers, 2003: 27-43
10. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-94
11. Eddy AA, McCulloch L, Liu E, et al. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 1991; 138: 1111-23
12. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-507
13. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-7
14. De Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment. Kidney Int 2004; 66 Suppl. 91: S2-6
15. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
16. Parving HH, Hovind P, Rossing K, et al. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001; 10: 515-22
17. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74
18. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7
19. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
20. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8
21. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
22. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
23. Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 292-300
24. Jerums G. Differences in renal outcomes with ACE inhibitors in type 1 and type 2 diabetic patients: possible explanations. Miner Electrolyte Metab 1998; 24: 423-37
25. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-5
26. Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-8
27. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
28. Gambaro G, Skrha J, Ceriello A. Glycosaminoglycan therapy for long-term diabetic complications? Diabetologia 1998; 41: 975-9
29. Tamsma JT, van den Born J, Brujin JA, et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37: 313-20
30. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806
31. Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-91
32. Oshima Y, Isogai S, Mogami K, et al. Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats. Diabetes Res Clin Pract 1995; 25: 83-9
33. Oturai PS, Rasch R, Hasseleger E, et al. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. APMIS 1996; 104: 259-64
34. Oturai PS. Effects of heparin on vascular dysfunction in diabetic rats. Clin Exp Pharmacol Physiol 1999; 26: 411-4
35. Van der Pijl JW, Lemkes HH, Frolich M, et al. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Nephrol 1999; 10: 1331-6
36. Nielsen S, Schmitz A, Bacher T, et al. Transcapillary escape rate and albuminuria in type II diabetes: effects of short-term treatment with low-molecular weight heparin. Diabetologia 1999; 42: 60-7
37. Striker GE, Lupia E, Elliot S, et al. Glomerulosclerosis, arteriosclerosis, and vascular graft stenosis: treatment with oral heparinoids. Kidney Int Suppl 1997; 63: S120-3
38. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol Rev 1996; 48: 327-52
39. Park HY, Kang S, Kim GY, et al. Inhibition of neointimal proliferation of rat carotid artery by sulodexide. J Korean Med Sci 1997; 12: 210-4
40. Gambaro G, Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11: 762-4
41. Ceol M, Gambaro G, Nerlich A, et al. Glycosaminoglycan therapy prevents TGF-β1 over-expression and pathological changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000; 11: 2324-36
42. Bobadilla NA, Tack I, Tapia E, et al. Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. J Am Soc Nephrol 2001; 12: 2080-7
43. Koppel H, Yard BA, Christ M, et al. Modulation of angiotensin II-mediated signalling by heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 2003; 18: 2240-7
44. Xu X, Rao G, Maxhimer JB, et al. Mechanism of action of sulodexide-mediated control of diabetic proteinuria: inhibition of heparanase-1 activity [abstract]. J Am Soc Nephrol 2005; 16: 673A
45. Gambaro G, van der Woude FJ. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11: 359-68
46. Caenazzo C, Garbisa S, Ceol M, et al. Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: molecular clues for its activity in nephropathy. Nephrol Dial Transplant 1995; 10: 175-84
47. Ceol M, Nerlich A, Baggio B, et al. Increased glomerular α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996; 74: 484-95
48. Weigert C, Brodbeck K, Haring HU, et al. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-β1 gene activation. Kidney Int 2001; 60: 935-43
49. Webb LM, Ehrengruber MU, Clark-Lewis I, et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci U S A 1993; 90: 7158-62
50. Ceol M, Vianello D, Schleicher E, et al. Heparin reduces glomerular infiltration and TGF-β protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol 2003; 16: 210-8
51. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-25
52. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab 2000; 26 Suppl. 4: 64-6
53. Solini A, Carraro A, Barzon I, et al. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria. Diabetes Nutr Metab 1994; 7: 304-7
54. Myrup B, Hansen PM, Jensen T, et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345: 421-2
55. Tamsma JT, van der Woude FJ, Lemkes HHPJ. Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type-1) nephropathy. Nephrol Dial Transplant 1996; 11: 182-5
56. Van der Pijl JW, van der Woude FJ, Geelhoed-Duijvestijn PHLM, et al. Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 1997; 8: 456-62
57. Poplawska A, Szelachowska M, Topolska J, et al. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract 1997; 38: 109-14
58. Sorrenti G, Grimaldi M, Canova N, et al. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients: a pilot study. J Int Med Res 1997; 25: 81-6
59. Skrha J, Perusicova J, Pontuch P, et al. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract 1997; 38: 25-31
60. Dedov I, Shestakova M, Vorontzov A, et al. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 2295-300
61. Szelanowska M, Poplawska A, Jopdska J, et al. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 1997; 13: 539-45
62. Velussi M, Cernigoi AM, Dapas F, et al. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diabetes Nutr Metab 1996; 9: 53-8
63. Solini A, Vergnani L, Ricci F, et al. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20: 819-23
64. Oksa A, Pontuch P, Kratochvilova H. The effect of glycosaminoglycan sulodexide on albuminuria in patients with diabetes mellitus [in Slovak]. Bratisl Lek Listy 1999; 100: 486-9
65. Achour A, Kacem M, Dibej K, et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005; 18: 568-74
66. Lewis EJ, Lewis JB, Hunsicker LG. Interim analysis of a pilot trial of sulodexide in type 2 diabetic nephropathy with microalbuminuria [abstract]. J Am Soc Nephrol 2005; 16: 58A
67. Source Keryx Biopharmaceuticals, Inc. Press release, November 14, 2005 [online]. Available from URL: http://www.shareholder.com/keryx/releases.cfm [Accessed 2006 Feb 20]
68. Effect of sulodexide in early diabetic nephropathy [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00130208 [Accessed 2006 Feb 20]
69. Effect of sulodexide in overt diabetic nephropathy. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00130312 [Accessed 2006 Feb 20]
70. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-80
71. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1988; 32: 219-26
72. Greive KA, Nikolic-Paterson DJ, Guimarães MAM, et al. Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol 2001; 159: 1159-70
73. Myers BD, Winetz F, Chui F, et al. Mechanisms of proteinuria in diabetic nephropathy: a study of glomerular barrier function. Kidney Int 1982; 21: 633-41
74. Hansen HP, Rossing P, Tarnow L, et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995; 47: 1726-31
75. Reddi AS, Ramamurthi R, Miller M, et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991; 45: 119-31
76. Condorelli M, Chiariello M, Daggianti A, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27-34
77. Gaddi A, Galetti C, Illuminati B, et al. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res 1996; 24: 389-406
78. Coccheri S, Scondotto G, Agnelli G, et al. Sulodexide in the treatment of intermittent claudication: results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J 2002; 23: 1057-65
79. Parnetti L, Mari D, Abate G, et al. VAscular Dementia Italian Sulodexide Study (VA.D.I.S.S.): clinical and biological results. Thromb Res 1997; 87: 225-33
80. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 1998; 18: 1-20
81. Larsen AK, Lund DP, Langer R, et al. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci U S A 1986; 83: 2964-8
82. Van der Pijl JW, van der Woude FJ, Swart W, et al. Effect of danaparoid sodium on hard exudates in diabetic retinopathy. Lancet 1997; 350: 1743-5
83. Rubbi F, Caramazza R, Boccia S, et al. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangiol 2000; 48 Suppl. 1: 81-2
84. Warkentin TE, Levine MN, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
85. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61
86. Hill GR, Hickton C, Henderson S, et al. The use of orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher orgaran concentrations. Clin Lab Haematol 1997; 19: 155-7